Carter HB - Search Results

1

Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.

Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ. Carter HB, et al. Urology. 2007 Oct;70(4):685-90. doi: 10.1016/j.urology.2007.05.010. Urology. 2007. PMID: 17991538 Free PMC article.

2

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Carter HB, Walsh PC, Landis P, Epstein JI. Carter HB, et al. J Urol. 2002 Mar;167(3):1231-4. J Urol. 2002. PMID: 11832703

3

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

Fang J, Metter EJ, Landis P, Carter HB. Fang J, et al. Among authors: carter hb. Urology. 2002 Jun;59(6):889-93; discussion 893-4. doi: 10.1016/s0090-4295(02)01646-1. Urology. 2002. PMID: 12031375

4

Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging.

Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ, Platz EA; Baltimore Longitudinal Study of Aging. Berndt SI, et al. Among authors: carter hb. Urology. 2002 Dec;60(6):1118-23. doi: 10.1016/s0090-4295(02)01991-x. Urology. 2002. PMID: 12475694

5

Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States).

Hsieh LJ, Carter HB, Landis PK, Tucker KL, Metter EJ, Newschaffer CJ, Platz EA. Hsieh LJ, et al. Among authors: carter hb. Urology. 2003 Feb;61(2):297-301. doi: 10.1016/s0090-4295(02)02120-9. Urology. 2003. PMID: 12597934

6

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Khan MA, et al. Among authors: carter hb. J Urol. 2003 Dec;170(6 Pt 1):2274-8. doi: 10.1097/01.ju.0000097124.21878.6b. J Urol. 2003. PMID: 14634395

7

Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging.

Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA. Hubbard JS, et al. Among authors: carter hb. Urology. 2004 Feb;63(2):253-8. doi: 10.1016/j.urology.2003.09.060. Urology. 2004. PMID: 14972466

8

Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.

Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Platz EA, et al. Among authors: carter hb. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):390-6. doi: 10.1158/1055-9965.EPI-04-0532. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15734963

9

Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?

Carter HB, Landis P, Wright EJ, Parsons JK, Metter EJ. Carter HB, et al. J Urol. 2005 Jun;173(6):2040-3. doi: 10.1097/01.ju.0000158372.45211.47. J Urol. 2005. PMID: 15879821

10

Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy.

Freedland SJ, Haffner MC, Landis PK, Saigal CS, Carter HB. Freedland SJ, et al. Among authors: carter hb. Urology. 2005 Jun;65(6):1131-6. doi: 10.1016/j.urology.2004.12.064. Urology. 2005. PMID: 15913722

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters